Upper extremity forearm atrophy; bilateral lower extremity tingling and numbness. Felt from the feet to the front of the calf/thighs to abdomen/ Diagnosed by PCP on 25Feb2022 with paresthesia of both lower extremities.; Bed/chair bound with loss of urine and bowel control; Bed/chair bound with loss of urine and bowel control; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 61-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 21Jan2022 at 11:00 as dose 3 (booster), single (gray cap) (Lot number: FJ6369) at the age of 60 years for covid-19 immunisation. The patient's relevant medical history included: "OSA" (unspecified if ongoing), notes: OSA; "Hyperlipidemia" (unspecified if ongoing); "Known allergies: Penicillins" (unspecified if ongoing), notes: Known allergies: Penicillins; "Prior to vaccination, was the patient diagnosed with COVID-19?:Yes" (unspecified if ongoing), notes: Prior to vaccination, was the patient diagnosed with COVID-19?:Yes. The patient's concomitant medications were not reported. Vaccination history included: covid-19 mrna vaccine - pfizer 12+ (purple cap) (Dose Number: 1. Batch/Lot No: EW0158. Covid-19 MRNA Vaccine - Pfizer 12+ (Purple Cap)), administration date: 13Apr2021, when the patient was 60-year-old, for COVID-19 Immunization; covid-19 mrna vaccine - pfizer 12+ (purple cap) (Dose Number: 2. Batch/Lot No: EW0173. Covid-19 MRNA Vaccine - Pfizer 12+ (Purple Cap)), administration date: 04May2021, when the patient was 60-year-old, for COVID-19 Immunization. The following information was reported: ANAL INCONTINENCE (disability), URINARY INCONTINENCE (disability) all with onset 20Feb2022, outcome "not recovered" and all described as "Bed/chair bound with loss of urine and bowel control"; ATROPHY (hospitalization) with onset 20Feb2022, outcome "not recovered", described as "Upper extremity forearm atrophy"; PARAESTHESIA (disability) with onset 20Feb2022, outcome "not recovered", described as "bilateral lower extremity tingling and numbness. Felt from the feet to the front of the calf/thighs to abdomen/ Diagnosed by PCP on 25Feb2022 with paresthesia of both lower extremities.". The patient was hospitalized for atrophy (start date: 03Mar2022). The events "upper extremity forearm atrophy", "bilateral lower extremity tingling and numbness. felt from the feet to the front of the calf/thighs to abdomen/ diagnosed by pcp on 25feb2022 with paresthesia of both lower extremities." and "bed/chair bound with loss of urine and bowel control" required physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (03Mar2022) Negative, notes: covid test type post vaccination=Nasal Swab; (10Mar2022) Negative, notes: covid test type post vaccination=Nasal Swab; (17Mar2022) Negative, notes: covid test type post vaccination=Nasal Swab; (21Mar2022) Negative, notes: covid test type post vaccination=Nasal Swab; (11Apr2022) Negative, notes: covid test type post vaccination=Nasal Swab; (12Apr2022) Negative, notes: covid test type post vaccination=Nasal Swab; (23Apr2022) Negative, notes: covid test type post vaccination=Nasal Swab; (03May2022) Negative, notes: covid test type post vaccination=Nasal Swab. Therapeutic measures were taken as a result of atrophy, paraesthesia, anal incontinence, urinary incontinence.  Clinical course: On 20Feb2022 the reporter was reported that had bilateral lower extremity tingling and numbness. Felt from the feet to the front of the calf/thighs to abdomen. Diagnosed by PCP on 25Feb2022 with paresthesia of both lower extremities. Hospitalized beginning 03Mar2022. During hospitalization, symptoms worsened and also diagnosed with bilateral upper extremity forearm atrophy. Now bed/chair bound with loss of urine and bowel control. Intensive rehabilitation at a long-term acute facility and short-term rehab facility with little improvement. Since the vaccination the patient had been tested for COVID-19. The adverse event result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient received treatment for the adverse event Solu-Medrol and PLEX. Since the vaccination, has the patient been tested for COVID-19 was reported as Yes. Device Date: 18Jul2022.  Follow-up attempts are completed. No further information is expected.